natgillin/translations-raw huggingface dataset:
The weight ratios specified below are based on the compound (b) expressed as (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane bromide and the free bases of the B2 agonists salmeterol and formoterol which are particularly preferred according to the invention. 
Dolje navedeni težinski omjeri temelje se na spoju (b) koji spoj je 3(R)-(2-hidroksi-2,2-ditien-2-ilacetoksi)-1-(3-fenoksipropil)-1-azoniabiciklo[2.2.2|oktan bromid i kortikosteroidima budesonidu i beklometazon dipropionatu koji su osobito poželjni sukladno predmetnom izumu.
Thus, the two jaw members 6, 7 can be moved relative to each other, wherein in the opened position as for example shown in Fig. 1 a capsule 24 can be inserted into the space confined by the two (distanced) jaw members 6, 7. 
Na taj način se mogu dva elementa čeljusti 6, 7 pomicati relativno jedan u odnosu na drugi, pri čemu u otvorenom položaju, kao što je, na primjer, prikazano na slici 1, čahura 24 može biti umetnuta u prostor koji je omeđen s dva elementa čeljusti 6, 7 (koji su razmaknuti).
The method 600 for welding the two or more conduit members 200, 300 as claimed in claim 5, wherein releasing the upward thrust by one of a hydraulically, a pneumatically, a mechanically or a thermally releasing arrangement 134. 
Postupak (600) za zavarivanje dva ili više elemenata vodova (200,300) kao što je navedeno u zahtjevu 4, naznačeno time da se potisak prema gore otpušta jednim od hidrauličkog, pneumatskog, mehaničkog ili termalnog otpuštajućeg sklopa (134).
TIP Tobramycin Inhalation Powder In one aspect the present invention provides methods for the treatment of endobronchial infections in a patient, comprising administering to the endobronchial system of the patient a dry powder aerosol composition comprising from 90 to 130 mg of an aminoglycoside antibiotic one to three times a day for a first treatment period of 20 to 36 days. 
Suhi sastav praškastog aerosola, naznačen time, da sadrži od 100 do 130 mg tobramicina po jednoj dozi za uporabu u liječenju endobronhijalne infekcije kod pacijenta koji pati od cistične fibroze, pri čemu se sastav primjenjuje na endobronhijalni sustav pacijenta, gdje se jedna doza sastava daje jednom do tri puta dnevno za vrijeme prvog perioda liječenja u trajanju od 20 do 36 dana.
The method of claims 1 to 4, wherein the trans-(-)-A9-tetrahydrocannabinol is present in the first composition in an amount from about 0.75 to about 1.25 molar equivalents, preferably from about 0.9 to about 1.1 molar equivalents, more preferably from about 0.95 to about 1.05 molar equivalents and even more preferably about 1 molar equivalent per molar equivalent of trans-(+)-A9-tetrahydrocannabinol. 
Postupak prema zahtjevima 1 do 4, naznačen time da je trans-(-)-A*-tetrahidrokanabinol prisutan u prvom sastavu u količini od oko 0.75 do oko 1.25 molarnih ekvivalenata, poželjno od oko 0.9 do oko 1.1 molarnih ekvivalenata, još poželjnije od oko 0.95 do oko 1.05 molarnih ekvivalenata i čak još poželjnije oko 1 molarni ekvivalent po molarnom ekvivalentu trans-(+)-A-tetrahidrokanabinola.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier; and a compound of claim 1. 
Farmaceutski sastav, naznačen time, da obuhvaća farmaceutski prihvatljiv nosač i spoj prema zahtjevu 1.
a demapper configured to demap the obtained signal frame into bits for the preamble symbols and bits for the data symbols; and a decoder configured to decode the bits for the preamble symbols by a shortened and punctured LDPC(low density parity check) decoding scheme, characterized in that the receiver is configured to process signals wherein the preamble symbols are divided into Layer 1 (L1) blocks, the bandwidth of each L1 block corresponding to a total number of active subcarriers assigned to a single channel and the L1 blocks being repeated in the frequency domain with a repetition rate being the bandwidth of the L1 block. 
Uređaj za prijam radiotelevizijskog signala, naznačen time, što uređaj obuhvaća: sredstva za prijam signalnog okvira koji uključuje simbole preambule i barem jedan podatkovni odsječak temeljen na simbolu podatkovnog servisa; sredstva za demodulaciju primljenog signalnog okvira korištenjem metode multipleksiranja s ortogonalnom podjelom frekvencija (OFDM); sredstva za premapiranje simbola preambule u podatkovne bitove preambule, te simbole podatkovnog servisa u bitove podatkovnog servisa; i sredstva za dekodiranje bitova preambula korištenjem skraćene i bušene LDPC (provjera pariteta niske gustoće) sheme dekodiranja; pri čemu su simboli preambule podijeljeni u frekvencijske osi u blokove sloja 1 (L1) iste širine pojasa, a širina pojasa pojedinog LI bloka odgovara jednom od 3408 podnosilaca pridijeljenih jednom kanalu.
The pharmaceutical composition in form of emulsion or microemulsion for use according to claim 1, wherein said composition has a viscosity below about 150 cP (centipoises), preferably below about 100 cP (centipoises), more preferably below about 50 centipoises cP (centipoises), much more preferably below about 20 cP (centipoises). 
Farmaceutski pripravak u obliku emulzije ili mikroemulzije prema zahtjevu 1, gdje taj pripravak ima viskoznost nižu od oko 0,15 Pa:s (150 cP), poželjno nižu od oko 0,1 Pa:s (100 cP), poželjnije nižu od oko 0,05 Pa:s (50 cP), još poželjnije nižu od oko 0,02 Pa:s (20 cP).
mg of said quinolone carboxylic acid derivative, wherein said quinolone carboxylic acid is delafloxacin meglumine; and mg of said effervescent agent. 
(a) 650 mg navedenog derivata kinolon karboksilne kiseline, gdje je navedena kinolon karboksilna kiselina delafloksacin meglumin; i
The crystalline form of Claim 1 which exhibits a differential scanning calorimeter thermogram having a single predominant endotherm at about 145.53°C at a scan rate of 10°C per minute, as shown in Figure 3.1, or the differential scanning calorimeter thermogram having a single predominant endotherm within the range of 144.01 to 146.92°C at a scan rate of 10°C per minute, as shown in Figure 3.2. 
Kristalni oblik u skladu s patentnim zahtjevom 1, naznačen time što pokazuje termogram diferencijalnog skenirajućeg kalorimetra s jednom prevladavajućom endotermom na otprilike 145,53 "C, pri brzini skeniranja od 10 *C u minuti, kao što je prikazano na Slici 3.1, ili termogram diferencijalnog skemirajućeg kalorimetra s jednom prevladavajućom endotermom u rasponu od 144,01 do 146,92 "C, pri brzini skeniranja od 10 "C u minuti, kao što je prikazano na Slici 3.2.
determining a prediction unit having a size equal to a size of the current coding unit or partitions into which at least one of a height and a width of the current coding unit is split based on the determined partition type, and performing intra prediction or inter prediction for the determined prediction unit or each of the determined partitions based on the determined prediction mode. 
HR P20182053 T1 određivač jedinice za kodiranje (120) generira informaciju o veličini jedinice za transformaciju od jedinice kodiranja dubine kodiranja, pri čemu se dobiva barem jedna jedinica za transformaciju, prema veličini transformacijske jedinice, dijeljenjem visine i širine jedinice kodiranja trenutne dubine ili da podatkovna jedinica bude iste veličine kao jedinica kodiranja trenutne dubine 1 transformacija se izvršava na jedinici kodiranja trenutne dubine temeljeno na barem jednoj transformacijskoj jedinici.
The process of claim 4, wherein the mixture in step (i) is heated to a temperature of 30 °C to 50 °C. 
Postupak prema zahtjevu 4, naznačen time, da se smjesa u koraku (i) zagrijava do temperature 30 "C do 50 *C.
A compound, tautomer or pharmaceutically acceptable salt according to claim 9, wherein R4b and R4c, together with the nitrogen and carbon atoms to which R4b and R4c are respectively attached, form an unsubstituted pyrrolidine ring. 
Spoj, tautomer ili farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 5-6, naznačen time da prsten koji tvore R4b i R4d, zajedno s dušikovim atomom i ugljikovim atomima na koje su R4b, R4c, i R4d odgovarajuće vezani, je nesupstituiran.
For the avoidance of doubt, the term (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane is meant to embrace the salts in dissociated, partially dissociated or undissociated form, for example in aqueous solution. 
Kako bi se izbjegle nedoumice, gore navedene formule i termin (3R)-1-fenetil-3-(9H-ksanten-9-karboniloks1)-1- azoniabiciklo[2.2.2]oktan obuhvaća soli u disociranom, djelomično disociranom ili nedisociranom obliku, na primjer u vodenoj otopini.
The polypeptide according to claim 1 or 2, wherein the polypeptide comprises an amino acid sequence having at least 90 %, preferably at least 95 %, more preferably at least 99 % sequence identity to SEQ ID NO: 2. 
Polipeptid u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da polipeptid obuhvaća aminokiselinski odsječak s najmanje 90 %, poželjno barem 95 %, a poželjnije je najmanje 99 % identičnosti odsječka sa SEQ ID NO: 2.
[Substituent group B] 
[Supstituentska skupina B]
with 9-borabicyclo[3.3.1]nonane (9-BBN), followed by reacting with a compound of Formula IIc: 
OCH2oCHa ceno Ilg s 9-borabiciklo[3.3.1]nonanom, nakon čega slijedi reakcija sa spojem s formulom IIc:
A system for the production of frames (27c) from material such as wire or strip or other material of prismatic cross section as claimed in any one of claims 1 to 6, further characterized by: 
Sustav za proizvodnju okvira (27c), od materijala, kao što su žica ili traka, ili drugi materijali prizmatičnog poprečnog presjeka, kao što se zahtjeva u zahtjevima 1 do 6, naznačeni time:
The concentration of the constituents in water may range from about 0.25% to 7% by weight, i.e., the dilute solution is comprised of from about 93% to about 99% by weight water. 
Koncentracija sastojaka u vodi može biti u opsegu od 0.25% do 7 masenih %, tj., razrjeđena otopina se sastoji od 93% do 99 masenih % vode.
The CTLA4-Ig composition of claim 1, wherein the CTLA4-Ig composition comprises less than or equal to 2.5 area percent high molecular weight species as determined by size exclusion chromatography and spectrophotometric detection. 
Pripravak prema zahtjevu 1, gdje su CTLA4-Ig molekule manje ili jednake 1.0 posto površine od vrsta visoke molekulske težine kako je određeno kromatografijom isključenja po veličini i spektrofotometrijskim otkrivanjem.
The method for the preparation of the agomelatine hydrobromide hydrate according to claim 4 or 6, wherein the reaction temperature is 0-20°C. 
Postupak za dobivanje agomelatin hidrobromid hidrata u skladu s patentnim zahtjevom 4 ili 6, naznačen time, da je temperatura reakcije od 0 do 20°C.
A compound according to claim 3 or a pharmacologically acceptable salt thereof, wherein R8a represents a C1-C4 alkyl group, and k represents 0. 
Spoj prema zahtjevu 3 ili njegova farmakološki prikladna sol, gdje R* predstavlja C,-C, alkil skupinu, i k predstavlja 0.
A light source as claimed in claim 16, claim 17 or claim 18, wherein the sealed plug is recessed and a second plug is provided in the counter-bore flush with the crucible at outer surfaces thereof. 
Svjetlosni izvor u skladu s patentnim zahtjevom 16, patentnim zahtjevom 17 ili s patentnim zahtjevom 18, naznačen time, da je hermetički zatvoreni čep upušten, a u upustivom dijelu nalazi se drugi čep koji je poravnat s vanjskom površinom retorte.
R2b, R3a and R3b are respectively and independently hydrogen, cyano, halogen, C1-6alkyl, C3-7cycloalkyl, C2-6alkenyl or C1-6alkoxy, said C1-6alkyl, C3-7cycloalkyl, C2-6alkenyl and C1-6alkoxy can optionally be substituted by 1, 2, 3 or 4 substituents independently selected from the group consisting of: halogen, cyano and carboxyl; 
b, R3a i R3b su respektivno i nezavisno vodik, cijano, halogen, C1-6alkil, C3-7cikloalkil, C2-6alkenil ili C1-6alkoksi, spomenuti C1-6alkil, C3-7cikloalkil, C2-6alkenil i C1-6alkoksi mogu izborno biti supstituirani s 1, 2, 3 ili 4 supstituenta nezavisno odabranih iz skupine koja se sastoji od: halogena, cijano i karboksila;
a dihydropyranyl group which can be substituted, a mono-(C1-10 alkyl-carbonyl)-amino group which can be substituted, a C1-10 alkoxy-carbonyl group which can be substituted, 
dihidropiranil-skupina koja može biti supstituirana; mono-(C1-10 alkil-karbonil)-amino-skupina koja može biti supstituirana; C1-10 alkoksi-karbonil-skupina koja može biti supstituirana;
A multidose dry powder inhaler device comprising aclidinium, which is calibrated to deliver, upon actuation, a fine particle dose of aclidinium equivalent to 120 µg (plus/minus 35%) aclidinium bromide. 
Višedozni inhalator suhog praha koji sadrži aklidinij, kalibriran da nakon aktiviranja isporuči odmjerenu nominalnu dozu aklidinija jednaku 400 mikrograma (plus/minus 10 %) aklidinijevog bromida.
A process to make fusidic acid cream as claimed in any of claim 2, 4, and 5 further wherein a buffering agent is added to the step a of claims 2 to 4, said buffering agent being selected from a group comprising Di Sodium Hydrogen Ortho Phosphate, Sodium Hydrogen Ortho Phosphate and the like from about 0.01 % (w/w) to 1.00% (w/w), preferably 0.5% (w/w), more preferably 0.05% (w/w). 
Postupak za proizvodnju kreme s fusidinskom kiselinom prema bilo kojem od patentnih zahtjeva 2, 4 1 5, naznačen time, da se nadalje puferski agens dodaje u stupnju a patentnog zahtjeva 2 do 4, kod čega se navedeni puferski agens odabire iz skupine koja sadrži dinatrijev hidrogenortofosfat, natrijev hidrogenortofosfat 1 slične, u količini od oko 0,001% (tež.) do 1,00% (tež.), prvenstveno 0,05% (tež.), pogodnije 0,5% (tež.).
allergic processes, hypersensitivity reaction (type I, II, III or IV), asthma or rhinitis; 
- - alergijski procesi, hipersenzitivne reakcije (tipa I, IL, III ili TV), astma, ili rinitis;
The computer program product of any one of claims 11 to 14, further comprising increasing the mobile phone account of the user (102) to include a balance for payment of goods or services from a merchant. 
Proizvod računalni program prema bilo kojem od zahtjeva 9 do 11, dalje sadržeći povećanje računa mobilnog telefona korisnika (102) da uključuje saldo za plaćanje roba ili usluga (105) od trgovca (104).
is selected from the group consisting of H, OH, OCH3, and OCH2CH3; 
R1 je odabran iz grupe koja se sastoji od H, OH, OCHr; i OCH2CHz;;
The composition for use in a method as in claim 18 or 19 for use in said method further comprising, prior to administering, diagnosing the eye of the mammal with an eye disorder that is suitably treated with chronic administration of a therapeutic agent. The composition for use in a method as in claim 20 wherein the eye disorder is elevated intraocular pressure. 
Pripravak za upotrebu u postupku prema patentnom zahtjevu 14, naznačen time, da postupak nadalje sadrži, prije primjene, dijagnosticiranje oka sisavca s poremećajem oka koji je prikladno tretiran s kroničnim davanjem terapeutskog sredstva, gdje je poželjno poremećaj oka povišen intraokularni tlak.
Floor panel according to any of the preceding claims, characterized in that the lock-up body (14) is a pivotable body. 
Podni panel prema patentnom zahtjevu 1 do 6, naznačen time što je element za blokiranje (12) napravljen koekstruzijom.
The compound according to the above-mentioned [1] or a salt thereof for use in the prophylaxis or treatment of obesity. 
Spoj prema zahtjevu 1 ili njegova sol za uporabu u profilaksi ili liječenju šećerne bolesti.
The peptide for use according to Claim 1, wherein said peptide includes non-peptide bonds. 
Peptid u skladu s patentnim zahtjevom 1, pri čemu peptid uključuje nepeptidne veze.
the separated zofenopril calcium is purified by washing with methanol by stirring the zofenopril calcium in methanol and filtering; and/or 
(x) izolirani zofenopril kalcij je pročišćen ispiranjem metanolom miješanjem zofenopril kalcija u metanolu i filtriranjem; i/ili
The method of claim 1 or 2, wherein said acute lymphoblastic leukemia (ALL) is refractory and/or relapsed ALL. 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je navedena akutna limfoblastična leukemija (ALL) refrakterna i/ili recidiv ALL.
More preferably, the CCBs to be used in the composition of the present invention is selected from the group consisting of amlodipine, bamidipine, felodipine, isradipine, lacidipine, lercanidipine, manidipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine, diltiazem, gallopamil, and verapamil. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da je navedeni CCB odabran iz skupine koju čine amlodipin, barnidipin, felodipin, izradipin, lacidipin, lerkanidipin, manidipin, nikardipin, nifedipin, nimodipin, nisoldipin, nitrendipin, diltiazem, galopamil i verapamil.
In particular, the atomiser 11 is formed as a portable inhaler and preferably operates without a propellent gas. 
Posebno, atomizer 11 je izrađen kao prenosivi inhalator i radi ponajprije bez potisnog plina.
These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like. 
Navedeni pripravci mogu sadržavati kao dodatak aktivnom sastojku, boje, korigense okusa, stabilizatore, pufere, umjetna i prirodna sladila, sredstva za dispergiranje, zgušnjivače i sredstva za povećanje topivosti.
The method of item 117, wherein the first selected component consists essentially of mixed plastic. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se prva odabrana komponenta sastoji u biti od mješovitog plastičnog materijala.
re-suspending the second precipitate to form a suspension; (d) mixing finely divided silicon dioxide (SiO2) with the suspension from step (c); 
re-suspendiranje prvog taloga stvorenog u koraku (b) za tvorbu suspenzije, obrada suspenzije stvorene u koraku (c) s deterdžentom,
SUMMARY According to a first aspect, a process is provided for the treatment of tobacco material wherein the tobacco material has a relatively constant TSNA content during the process, the process comprising securing tobacco material within a moisture-retaining material and exposing the tobacco material to an ambient temperature of at least 45° C., wherein the tobacco material has a packing density on a dry matter weight base of at least 200 kg/m3 at the start of the process and has a moisture content of between about 10% and 23% before and during treatment. 
Postupak obrade duhanskog materijala, gdje obrađeni duhanski materijal ima sadržaj TSNA koji se nije povećao za više od 0,25 mg/g tijekom postupka, naznačen time što se postupak sastoji u sušenju duhanskog materijala unutar materijala koji zadržava vlagu i izlaganju duhanskog materijala okolišnoj temperaturi obrade od najmanje 45 *C, gdje duhanski materijal ima gustoću pakiranja na osnovi težine suhe tvari od najmanje 200 kg/m? na početku postupka i ima sadržaj vlage između 10 % 1 23 % prije i tijekom obrade.
A domain antibody (dAb) that binds to CD28 and prevents the binding of CD28 to CD80 and/or CD86, comprising a CDR1 sequence, a CDR2 sequence and a CDR3 sequence selected from the group consisting of: 
Antitijelo sa jednim imunoglobulinskim varijabilnim domenom koje se vezuje za CD28, koje sadrži CDR1 sekvencu sa SEQ ID NO:636, CDR2 sekvencu sa SEQ ID NO:637, i CDR3 sekvencu sa SEQ ID NO:638.
Number of positive bursa/total 
Broj međunarodne objave:
Process for recovery of sulphuric acid from a mixture comprising sulphuric acid and organic matter, comprising the step of contacting said mixture with an anion selective membrane, thus producing a sulphuric acid rich filtrate stream and a stream depleted in sulphuric acid, wherein said mixture originates from a contacting step wherein biomass is contacted with a fresh stream of sulphuric acid, and wherein said fresh stream of sulphuric acid is at least partly obtained from the filtrate that is obtained by said step of contacting said mixture with said anion selective membrane, and wherein said fresh stream of sulphuric acid further contains sulphuric acid that is obtained by burning H2S, which H2S is preferably obtained from a sulphate reduction step that is applied to a stream that is obtained from said stream depleted in sulphuric acid. 
Postupak za oporavljanje sumporne kiseline iz mješavine koja sadrži sumpornu kiselinu i organske tvari, naznačen time, da sadrži fazu spajanja spomenute mješavine s anionski selektivnom membranom, te time proizvodnju toka bogatog filtrata sumporne kiseline i ispražnjenje tijeka u sumpornoj kiselini, pri čemu spomenuta mješavina potiče iz faze spajanja gdje je biomasa u doticaju sa svježim tokom sumporne kiseline, i pri čemu je spomenuti svježi tok sumporne kiseline barem djelomično dobiven iz filtrata koji je dobiven u spomenutoj fazi spajanja spomenute mješavine sa spomenutom anionski selektivnom membranom, te pri čemu spomenuti svježi tok sumporne kiseline nadalje sadrži sumpornu kiselinu koja je dobivena izgaranjem H>S, a taj H,S je dobiven najbolje iz faze redukcije sulfata, koja se primjenjuje na tok koji je dobiven iz spomenutog ispražnjenja toka u sumpornoj kiselini.
The method as claimed in claim 23, wherein the diagnostic test is binding with a tissue-specific antibody; AND/OR, wherein the diagnostic test is binding with a tumor-specific antibody; AND/OR, wherein the diagnostic test comprises analyzing nucleic acids obtained from the at least one segregated circulating tumor cell that was present; AND/OR, wherein the diagnostic test is assessing the proliferative capacity of the segregated circulating tumor cell; AND/OR, wherein the diagnostic test is microscopic observation of the morphology of the segregated circulating tumor cell. 
Postupak za koji se zaštita patentom traži u patentnom zahtjevu 23, pri čemu se dijagnostičko ispitivanje vezuje sa antitijelom specifičnim za tkivo; VILI, pri čemu se dijagnostičko ispitivanje vezuje sa antitijelom specifičnim za tumor; I/ILI, pri čemu dijagnostičko ispitivanje obuhvaća analiziranje nukleinskih kiselina dobivenih iz najmanje jedne odvojene cirkulirajuće stanice tumora koja je bila prisutna; I/ILI, pri čemu dijagnostičko ispitivanje je procjena proliferativnog kapaciteta odvojene cirkulirajuće stanice tumora; VILI, pri čemu dijagnostičko ispitivanje je mikroskopsko promatranje morfologije odvojene cirkulirajuće stanice tumora.
As illustrative but nonlimiting examples of monoesters mentioned in b1), mention may be made of esters of saturated or unsaturated C2-C20 acids, such as acetates, propionates, butyrates, methylbutyrates, pentanoates, hexanoates, heptanoates, caproates, oleates, linoleates or linolenates of ethyl, propyl, butyl, pentyl, 2-methylbutyl, isoamyl, hexyl, benzyl, phenylethyl, menthyl, carvyl, and the like, and also mixtures thereof. 
Pripravak prema zahtjevu 7, gdje se b1) odabire između estera zasićenih ili nezasićenih C2-C2o kiselina, kao što su acetati, propionati, butirati, metilbutirati, pentanoati, heksanoati, heptanoati, kaproati, oleati, linoleati ili linolenati etila, propila, butila, pentila, 2-metilbutila, izoamila, heksila, benzila, feniletila, mentila, karvila, i slično, i također njihove smjese.
Examples of such diseases and conditions include, but are not limited to, B-cell Non-Hodgkin's lymphomas, such as small lymphocytic lymphoma, lymphoplasmacytoid lymphoma, mantle cell lymphoma, follicular lymphoma, mucosa-associated lymphoid tissue lymphoma, diffuse large cell lymphoma, and Burkitt's lymphoma; precursor B-lymphoblastic leukemia; and B-cell chronic lymphocytic leukemia, and multiple myeloma. 
Protutijelo, funkcionalni protein ili farmaceutski sastav za uporabu prema zahtjevu 24, naznačen/o time, da non-Hodgkin limfomi B-stanice su sljedeći: mali limfocitni limfom, limfoplazmacitoidni limfom, limfom plaštenih stanica, folikularni limfom, limfom tkiva povezan s limfoidnom mukozom, limfom velikih difuznih stanica 1 Burkittov limfom; prethodnik B-limfoblastne leukemije; i kronična limfocitna leukemija B-stanica, i višestruki mijelom.